• 1
    Bousquet J, Lockey RF, Malling HJ. WHO Position Paper; Allergen immunotherapy: therapeutic vaccines for allergic diseases. J Allergy Clin Immunol 1998;102: 558562.
  • 2
    Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E, Björksten B, Bousquet J, Caillot D et al. Position paper: local immunotherapy. Allergy 1998;53: 933944.
  • 3
    Bufe A, Gehlhar K, Schramm G, Schlaak M, Becker W-M. Allergenic activity of a major pollen allergen is elevated in the presence of nasal secretion. Am J Respir Crit Care Med 1998;157: 12691276.
  • 4
    Bagnasco M, Mariani G, Passalacqua G, Motta C, Bartolomei M, Falagiani P et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 1997;100: 122129.
  • 5
    Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis [see comments]. Lancet 1998;351: 629632.
  • 6
    Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998;53: 493498.
  • 7
    Gehlhar K, Schlaak M, Becker W-M, Bufe A. Monitoring specific immunotherapy of pollen allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 1999;29: 497506.
  • 8
    Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999;54: 249260.
  • 9
    Dreborg S. Skin-prick test. Allergy 1985;40: 5559.
  • 10
    Bufe A, Becker W-M, Schramm G, Petersen A, Mamat U, Schlaak M. Major allergen Phl p Va (timothy grass) bears at least two different IgE-reactive epitopes. J Allergy Clin Immunol 1994;94: 173181.
  • 11
    Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo- controlled study 64. Allergy 2000;55: 842849.
  • 12
    La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica G. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104: 425432.
  • 13
    Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998;53: 461472.
  • 14
    Giovane AL, Bardare M, Passalacqua G, Ruffoni S, Scordamaglia A, Ghezzi E et al. A three-year double-blind placebo-controlled study with specific oral immunotherapy to dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 1994;24: 5359.
  • 15
    Passalacqua G, Albano M, Riccio AM, Scordamaglia A, Canonica GW. Local nasal immunotherapy: experimental evidences and general considerations. Allergy 1997;52: 1016.
  • 16
    Batard T, Weyer A, Laroze A, Ickovic M-R, David B, Peltre G et al. Isotypic analysis of grass pollen-specific antibodies in human plasma. 4. Biological activity of allergen-specific and autoanti-IgE antibody fractions on basophil histamine release. Clin Exp Allergy 1996;26: 13081315.
  • 17
    Daeron M, Malbec O, Latour S, Arock M, Fridman WH. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995;95: 577585.